These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 9222272)

  • 41. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug treatment of Parkinson's disease.
    Quinn N
    BMJ; 1995 Mar; 310(6979):575-9. PubMed ID: 7888935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Neurological common diseases in the super-elder society. Topics: IV. Parkinson's disease; 2. Current and new drugs for initial treatment of Parkinson's disease].
    Hasegawa T
    Nihon Naika Gakkai Zasshi; 2014 Aug; 103(8):1861-8. PubMed ID: 25654881
    [No Abstract]   [Full Text] [Related]  

  • 44. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parkinson's disease. Diagnosis and the initiation of therapy.
    Bhat V; Weiner WJ
    Minerva Med; 2005 Jun; 96(3):145-54. PubMed ID: 16175158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zydis selegiline in the management of Parkinson's disease.
    Poston KL; Waters C
    Expert Opin Pharmacother; 2007 Oct; 8(15):2615-24. PubMed ID: 17931095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
    Olanow CW
    J Neural Transm Suppl; 1996; 48():75-84. PubMed ID: 8988463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Possible neuroprotective therapy for Parkinson's disease.
    Ogawa N
    Acta Med Okayama; 1995 Aug; 49(4):179-85. PubMed ID: 7502677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].
    Kuhn W; Müller T
    Fortschr Neurol Psychiatr; 1997 Aug; 65(8):361-74. PubMed ID: 9378449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroprotection and dopamine agonists.
    Schapira AH
    Neurology; 2002 Feb; 58(4 Suppl 1):S9-18. PubMed ID: 11909981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurotoxicity and neuroprotection in Parkinson's disease.
    Lange KW; Youdim MB; Riederer P
    J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Do dopamine agonists provide neuroprotection?
    Yamamoto M
    Neurology; 1998 Aug; 51(2 Suppl 2):S10-2. PubMed ID: 9711974
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targets for neuroprotection in Parkinson's disease.
    Yacoubian TA; Standaert DG
    Biochim Biophys Acta; 2009 Jul; 1792(7):676-87. PubMed ID: 18930814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Neuroprotective and neurorestorative therapy in Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of Parkinson's disease. From theory to practice.
    Ahlskog JE
    Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes].
    Szczudlik A; Rudzińska M
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S6-9. PubMed ID: 17941452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.